ClinicalTrials.gg
RecruitingNCT07587658MISSIONUpdated Oct 16, 2026

This After Market Study is Seeing if Dupilumab Plus Usual Standard of Care (SOC) is Better Than Usual Care Alone for Adult Participants After a Severe Chronic Obstructive Pulmonary Disease (COPD) Flare-Up Requiring Hospitalization

A Phase 4 interventional study of dupilumab and Placebo in Chronic Obstructive Pulmonary Disease (COPD), sponsored by Regeneron Pharmaceuticals. Recruiting at 1 site in United States. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2026-10-16.

Sponsored by Regeneron Pharmaceuticals · Phase 4, Interventional, and Treatment

From the registry’s dates

  • Started Oct 2026; still recruiting 1 month later.
Updated Oct 16, 2026Now RecruitingFirst site in United States+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
754
Allocation
Randomized
Ages
40 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 1,278 studies in Pulmonary Disease, Chronic Obstructive with a site in United States — 137 open to participants now, 172 under way, 20 of them phase 3. Pulmonary Disease, Chronic Obstructive · United States.

Planned enrollment
155th of 1,037
754 · median 100
Started
2026
with 38 others
Phase 4
98 of 1,278
6 open now
Primary completion
2028-07
later than 117 of 171 live
Registered
1,253rd of 1,278
by date

Among the 1,278 studies in Pulmonary Disease, Chronic Obstructive with a site in United States, this one is the 155th largest by planned enrollment of the 1,037 interventional ones that give a count, is one of 39 that started in 2026, is one of 98 in phase 4, reaches primary completion later than 117 of the 171 other live ones, and was the 1,253rd registered.

Pulmonary Disease, Chronic Obstructive

5,523 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 856 are open to participants now.

Browse Pulmonary Disease, Chronic Obstructive studies →

Open to participants now

137 of the 1,278 studies in Pulmonary Disease, Chronic Obstructive with a site in United States are open now. Recruiting first, the newest first:

131 more — sign in →

All 137 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 558 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 29 take children under 18; 88 take healthy volunteers.

This study: 40 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,278 studies in Pulmonary Disease, Chronic Obstructive with a site in United States, or all of them as a file.
02

Study summary

This study is researching a drug called dupilumab, referred to as "study drug". The study is focused on people diagnosed with COPD to determine if the study drug, in addition to standard of care treatment for COPD, might reduce the reoccurrence of a COPD exacerbation (a "flare-up") happening within the study treatment duration (around 90 days).

The study is looking at another research question:

  • What side effects may happen from taking the study drug
03

Conditions studied

  • Chronic Obstructive Pulmonary Disease (COPD)

Keywords

  • Moderate and/or Severe Exacerbation
  • Eosinophilic phenotype
  • Elevated blood eosinophil counts
  • Type 2 inflammation
  • dupilumab
04

Who can participate

Ages eligible
40 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  1. Has a clinical diagnosis of prior to randomization, as defined in the protocol
  2. Hospitalized or admitted to the ED >24 hours (from time of first admission or presentation to the ED) for acute exacerbation of COPD as primary diagnosis according to the principal investigator and exacerbation is managed by Systemic (SCS) ± antibiotics and other appropriate treatments as per SOC
  3. Elevated blood eosinophil counts during the current exacerbation, as defined in the protocol. The exacerbation event starts from the day Systemic Corticosteroids (SCS) ± antibiotics are administered continuously up to the day they presented to ED/hospital

Key Exclusion Criteria:

  1. Clinical evidence of pneumonia as the primary cause of admission in the investigator's opinion or acquired during hospital stay
  2. Complicating pulmonary conditions during the 8 weeks prior to randomization which may confound treatment assessments, as defined in the protocol
  3. pulmonary diseases other than COPD which may impair lung function and interfere with treatment assessments
  4. Participants with clinically significant α-1 anti-trypsin deficiency which may impair lung function and interfere with treatment assessments
  5. Cardiac-related comorbidity, as defined in the protocol
  6. Treatment with invasive mechanical ventilation in-hospital during the index event, as defined in the protocol
  7. Any biologic therapy or biologic Medicinal Product (IMP) to treat type 2 inflammatory diseases within 6 months prior to the screening visit or 5 half-lives, whichever is longer, as defined in the protocol

NOTE: Other Protocol-defined Inclusion/Exclusion Criteria Apply

Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
754 participants (estimated)

Study arms

  • Experimental
    dupilumab

    Drug: dupilumab

  • Placebo comparator
    Placebo

    Drug: Placebo

Interventions

  • Administered per the protocol

    Also known as: Dupixent®, REGN668, SAR231893

  • DrugPlacebo

    Administered per the protocol

06

What researchers measure

Primary outcomes

  1. Time to first all-cause event

    All-cause event may include non-elective hospital readmission, Emergency Department (ED)/urgent care visit, or death

    Time frame: Through day 90

  2. Number of moderate or severe COPD exacerbations

    Time frame: Through day 90

Secondary outcomes

  1. Time to first COPD-related event

    COPD-related event may include non-elective hospital readmission, Emergency Department (ED)/urgent care visit, or death

    Time frame: Through day 90

  2. Time to first moderate and/or severe COPD exacerbation

    Time frame: Through day 90

  3. Number of all-cause non-elective hospital readmissions

    Time frame: Through day 90

  4. Number of ED visits

    Time frame: Through day 90

  5. Number of COPD-related hospital readmissions

    Time frame: Through day 90

  6. Number of COPD-related ED visits

    Time frame: Through day 90

  7. Number of all-cause deaths

    Time frame: Through day 90

  8. Number of COPD-related deaths

    Time frame: Through day 90

  9. Occurrence of all-cause non-elective hospital readmissions

    Time frame: Through day 60

  10. Occurrence of all-cause ED visits

    Time frame: Through day 60

  11. Occurrence of all-cause deaths

    Time frame: Through day 60

  12. Occurrence of COPD-related hospital readmissions

    Time frame: Through day 60

  13. Occurrence of ED visits

    Time frame: Through day 60

  14. Occurrence of deaths

    Time frame: Through day 60

  15. Change in Chronic Airways Assessment Test (CAAT) score

    CAAT is a PRO measure that assesses the impact of lung disease on a person's life using an 8-item questionnaire with a 40-point scale with higher scores indicating worse disease.

    Time frame: From baseline through day 90

  16. Change in EXAcerbation of Chronic pulmonary disease Tool (EXACT) questionnaire score

    EXACT is a patient-reported daily diary that captures respiratory symptoms in COPD using a 14-item questionnaire with a 0 to 100-point scale with higher scores indicating worse disease symptoms.

    Time frame: From baseline through day 90

  17. Occurrence of Treatment-Emergent Adverse Events (TEAEs)

    Time frame: Through day 90

  18. Occurrence of Serious Adverse Events (SAEs)

    Time frame: Through day 90

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — All Individual Patient Data (IPD) that underlie publicly available results will be considered for sharing.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code

Time frame: When Regeneron has: received marketing authorization from major health authorities (e.g., FDA, European Medicines Agency (EMA), Pharmaceuticals and Medical Devices Agency (PMDA), etc.) for the product and indication or has globally discontinued development of the product for all indications on or after April 2020 and has no plans for future development made the study results publicly available (e.g., scientific publication, scientific conference, clinical trial registry) the legal authority to share the data, and ensured the ability to protect participant privacy

Access criteria: Qualified researchers can submit a proposal for access to individual patient or aggregate level data from a Regeneron-sponsored clinical trial through Vivli. Regeneron's Independent Research Request Evaluation Criteria can be found at: https://www.regeneron.com/sites/default/files/Regeneron-External-Data-Sharing-Policy-and-Independent-Research-Request-Evaluation-Criteria.pdf

Data sharing details ↗ · vivli.org

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2026 (actual). Primary completion is estimated for Jul 2028, 21 months after the start.

Of 71 industry-sponsored phase 4 interventional studies under Pulmonary Disease, Chronic Obstructive, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 22. This study's planned 21 months is above that.

Counting every sponsor, half of 157 studies reached it within 19 months; a quarter within 12 and three quarters within 40.

Start moved once since we started tracking on Sep 25, 2026: Jun 2026 → Oct 2026, on Oct 16, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
May 8, 2026
First posted
May 14, 2026
StartActual
Oct 6, 2026was Jun 2026
Primary completionEst.
Jul 30, 2028
CompletionEst.
Jul 30, 2028
Last update
Oct 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Oct 16, 2026
Sites
1 site added — first site in United States
Show site
  • Inspira Medical Center Mullica Hill · Mullica Hill, United States
Oct 16, 2026
Start date
Jun 30, 2026→Oct 6, 2026 (actual)
Oct 16, 2026
Show all 1 update
  1. Oct 16, 2026
    Not yet recruiting→Recruiting
    1 site added — first site in United States
    Show site
    • Inspira Medical Center Mullica Hill · Mullica Hill, United States
    Start date Jun 30, 2026→Oct 6, 2026 (now actual)
    + 2 other changes: identifiers and verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07587658
Collaborators
Sanofi
Responsible party
Sponsor
First posted
May 14, 2026
Start date
Oct 6, 2026
Primary completion
Jul 30, 2028 (estimated)
Completion
Jul 30, 2028 (estimated)
Last update
Oct 16, 2026

Study contacts

Clinical Trials Administrator
Contact
clinicaltrials@regeneron.com
844-734-6643
Clinical Trial Management
study director · Regeneron Pharmaceuticals

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dupilumab

Start the discussion